ascending SMCs showed that apoptotic SMCs have increased elastolytic potential compared with viable cells, mostly because of caspase activity. Moreover, in vitro (1) cell membrane isolation, (2) immunofluorescence staining, and (3) scanning electron microscopy studies illustrate that caspases are expressed on the exterior cell surface of apoptotic SMCs. 
A ortic root aneurysm rupture and dissection remain the leading causes of death in patients with the Marfan syndrome (MFS), a hereditary connective tissue disorder that affects 1 in 5000 individuals worldwide. 1 A heterozygous mutation in the fibrillin-1 (Fbn1) gene on chromosome 15q21.1 (OMIM 154700) causes impaired synthesis, secretion, and deposition of Fbn1, 2 ultimately resulting in enhanced transforming growth factor-β (TGF-β) signaling. 3 Importantly, the molecular mechanism(s) by which enhanced systemic TGF-β signaling results in aneurysm development localized to the ascending aorta only remains unknown.
See cover image
Using a MFS mouse model (Fbn1 C1039G/+ ), we recently reported that increased TGF-β signaling enhances the expression of the microRNA, miR-29b within the aortic root/ascending aorta only, a known regulator of downstream apoptotic and extracellular matrix (ECM) genes. 4 In vivo silencing of miR-29b with a locked nucleic acid miR-29b inhibitor significantly reduces ascending aorta diameter, coinciding with a reduction in ECM remodeling and apoptosis. 4 Although investigators have suggested that increased apoptosis of vascular smooth muscle cells (SMCs) contributes to aortic aneurysm development in various model systems, 5, 6 the pathological role in MFS remains controversial. 4, 7 © 2014 American Heart Association, Inc. Objective-Rupture and dissection of aortic root aneurysms remain the leading causes of death in patients with the Marfan syndrome, a hereditary connective tissue disorder that affects 1 in 5000 individuals worldwide. In the present study, we use a Marfan mouse model (Fbn1 C1039G/+ ) to investigate the biological importance of apoptosis during aneurysm development in Marfan syndrome. Approach and Results-Using in vivo single-photon emission computed tomographic-imaging and ex vivo autoradiography for Tc99m-annexin, we discovered increased apoptosis in the Fbn1 C1039G/+ ascending aorta during early aneurysm development peaking at 4 weeks. Immunofluorescence colocalization studies identified smooth muscle cells (SMCs) as the apoptotic cell population. As biological proof of concept that early aortic wall apoptosis plays a role in aneurysm development in Marfan syndrome, Fbn1 C1039G/+ mice were treated daily from 2 to 6 weeks with either (1) a pan-caspase inhibitor, Q-VD-OPh (20 mg/kg), or (2) vehicle control intraperitoneally. Q-VD-OPh treatment led to a significant reduction in aneurysm size and decreased extracellular matrix degradation in the aortic wall compared with control mice. In vitro studies using Fbn1
Accordingly, in the present study we use Fbn1 C1039G/+ mice to investigate the biological importance of apoptosis during the early pathogenesis of aneurysm development in MFS.
Herein, we demonstrate increased apoptosis within the Fbn1 C1039G/+ aortic root/ascending aorta with both in vivo and ex vivo imaging. Moreover, SMCs seem to be the most frequent apoptotic cell type within the aortic wall. When apoptosis is blocked with an irreversible pan-caspase-inhibitor (Q-VDOPh), aneurysm development in Fbn1 C1039G/+ mice is significantly reduced. Interestingly, apoptotic blockade is associated with reduced media vessel wall elastin breakdown. In vitro studies reveal that during apoptosis, caspases are expressed on the cell surface of SMCs and possibly play a part in the ECM degradation, contributing to aneurysm formation in MFS.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. 
Results

Apoptosis is Increased in the Aortic
Mice During Early Aneurysm Development
As we have previously described, during early aneurysm development, apoptotic markers (caspases-3 and -9) increase and antiapoptotic proteins (Bcl-2 and Mcl-1) decrease within the Fbn1 C1039G/+ aortic wall compared with wild-type (WT) littermate control. 4 To confirm these findings, we performed in vivo single-photon emission computed tomographic-imaging measuring Tc99m-annexin V-128 uptake in the aortic wall ( Figure 1A Figure 1C ).
To identify the specific cell population within the aortic wall undergoing apoptosis in Fbn1 C1039G/+ mice, immunofluorescence colocalization studies were performed to stain for apoptosis (cleaved caspase-3), in combination with cell-specific markers to detect smooth muscle cells (α-smooth muscle actin), endothelial cells (CD31), or fibroblasts (DDR2). Colocalization of cleaved caspase-3 and SMCs was observed within the aortic root/ascending aorta aortic wall media of Fbn1 C1039G/+ mice ( Figure 1D) Figure 1E ). To explain similar total SMC counts despite increased SMC apoptosis, immunohistological staining for the proliferation marker proliferating-cell-nuclear-antigen was performed and demonstrated increased positive staining in Fbn1 C1039G/+ compared with WT mice ( Figure 1F ). Together, these findings suggest that the SMC population undergoes increased apoptosis and is followed by a compensatory proliferative response during early aneurysm development in MFS.
Treatment of Fbn1
C1039G/+ Mice with a PanCaspase Family Inhibitor (Q-VD-OPh) Reduces Aortic Wall Apoptosis, Elastin Breakdown, and Early Aneurysm Development
As biological proof of concept that early aortic wall apoptosis plays a role in aneurysm development in Marfan mice, we treated Fbn1 C1039G/+ and WT mice with a pan-caspase inhibitor (Q-VD-OPh). Mice were treated daily beginning at 2 weeks until 6 weeks, the time point when apoptosis returns toward the baseline. 4 Q-VD-OPh decreased aortic wall apoptosis compared with vehicle control, as evidenced by reduced immunohistological staining for cleaved (active) caspase-3 ( Figure 2A and 2B) . Importantly, Q-VD-OPh treatment also significantly reduced aortic diameter at 3, 4, 5 and, 6 weeks in the Fbn1 C1039G/+ mice although the diameters remain greater than WT control ( Figure 2C ), confirming that apoptosis participates in the pathogenesis of early aneurysm development. Although we have reported increased aortic wall thickness in Fbn1 C1039G/+ versus WT mice at 32 weeks, 8 no significant difference was detected at 2 to 6 weeks. Moreover, no difference in wall thickness was distinguished when comparing Q-VD-OPh versus vector control-treated Fbn1 C1039G/+ mice (data not shown). Interestingly, coinciding with reduced apoptosis and aneurysm size, Q-VD-OPh treatment also resulted in less thinning of the elastin laminae (data not shown) and a significant decrease in aortic wall elastin fragmentation when compared with vehicle control treatment ( Figure 2D and 2E).
To determine whether SMC apoptosis in MFS is indeed a TGF-β-dependent phenomenon, Fbn1 C1039G/+ mice were treated with either a pan-sensitive TGF-β neutralizing antibody or mouse IgG (vector control) from 2 to 4 weeks. Confirming our hypothesis, TGF-β blockade significantly reduced caspase-3 positive staining, suggesting that apoptosis is linked to TGF-β signaling in our model system ( Figure 2F ). Although apoptosis seems to contribute to the pathogenesis of aneurysm development in MFS, the molecular mechanism accounting for this effect is unknown. To define a mechanistic link between apoptosis and ECM degradation during early aneurysm development, we performed colocalization histological staining for cleaved (active) caspase-3 and lectin, a cell membrane-specific marker, in Q-VD-OPh versus vehicle control-treated animals. Interestingly, cleaved caspase-3, in part, localizes to the cell membrane, perhaps contributing to the elastin breakdown noted during ECM remodeling in Marfan mice. Noteworthy, histological staining alone cannot determine whether caspase-3 is expressed on the internal or external surface of the cell membrane ( Figure 3A ).
Apoptotic Aortic Root/Ascending Aortic Smooth Muscle Cells Induce Elastin Degradation
To investigate further our hypothesis that active caspases localized to the surface of apoptotic cells can degrade the ECM in the aortic root/ascending aorta of Fbn1 C1039G/+ mice further, we first determined whether excessive TGF-β1 signaling (noted in the mutant phenotype), induces SMC apoptosis, in vitro. Starved Fbn1 C1039G/+ and WT aortic root/ascending SMCs were incubated with either vehicle (control) or recombinant TGF-β1 for 48 hours. Apoptosis was assessed using (1) DePsipher, a mitochondrial membrane potential dye, which exhibits both red and green fluorescence in cells with intact mitochondrial membrane potentials (viable cells) versus green fluorescence alone in cells with impaired mitochondrial membrane potentials (apoptotic cells) ( Figure 3B ) and (2) caspase-3 activity assay. TGF-β1 induced apoptosis in aortic root/ascending aortic SMCs derived from both Fbn1 , P<0.05, n=3), suggesting that elevated TGF-β1 alone may not be sufficient to cause the mutant phenotype ( Figure 3C ). Confirming that TGF-β1 induces apoptosis, whereas caspase inhibition reduces apoptosis in vitro, Q-VD-OPh treatment significantly reduced caspase activity in both the control and TGF-β1-treated Fbn1 C1039G/+ aortic root/ascending SMCs ( Figure 3D ). Because Cowan 9 et al reported that caspases released or exteriorized to the cell surface of apoptotic SMCs may potentially degrade the ECM in vitro, 9 we investigated the elastolytic activity of Fbn1 C1039G/+ aortic root/ascending SMCs undergoing apoptosis. Apoptosis was induced with either TGF-β1 or staurosporine (positive control). Elastolytic activity in both TGF-β1 and staurosporine-treated groups (apoptotic) was significantly higher than in viable cells (control) ( Figure 4A ). To define which enzyme(s) degrade elastin in vitro better, [9] [10] [11] we selectively inhibited elastase (N-methoxysuccinyl-AlaAla-Pro-Val-chloromethyl), matrix metalloproteinases (GM-6001), or caspases (Q-VD-OPh). Although elastase blockade was ineffective, both MMP-and caspase-inhibition significantly reduced the elastolytic activity of apoptotic Fbn1 C1039G/+ ascending SMCs ( Figure 4B ). Then, to assess whether Q-VDOPh decreases elastolytic activity directly via caspase inhibition further, we repeated the assay but with additive enzyme inhibition. After blocking both elastase-and MMP-activity, Q-VD-OPh had an additional inhibitory effect suggesting that it acts through caspase-inhibition ( Figure 4C ).
Elastolytic Caspases are Active on Apoptotic Fbn1
C1039G/+ Aortic Root/Ascending Aortic Smooth Muscle Cell Membranes, In Vitro After finding that caspases from apoptotic Fbn1 C1039G/+ aortic root/ascending SMCs are capable of degrading elastin in vitro, we explored the elastolytic potential of caspases: (1) released into the surrounding environment or (2) exteriorized to the cell membrane. To help answer this question, elastolytic activity assays were performed on conditioned media, cytoplasm, or isolated cell membrane fractions from apoptotic Fbn1 C1039G/+ aortic root/ascending SMCs. While elastolytic activity was not different in the conditioned media from control versus apoptotic SMCs (data not shown), it was significantly increased in both the cytosolic and the membrane fractions of apoptotic when compared with nonapoptotic SMCs (Figure 4D and 4E) . These data suggest that elastolytic enzymes are not released into the media after SMC apoptosis, but instead localized to the cytosol and plasma cell membrane. Western blot analyses corroborated that caspase-3 is significantly elevated in both the cell membrane and the cytosolic fractions after apoptosis ( Figure 4F and 4G), with efficiency of fraction separation confirmed by testing for the membrane-specific protein, plasma membrane calcium pump ATPase ( Figure 4H ). Even more, treatment with Q-VD-OPh decreased the elastolytic activity of the membrane fraction, thus supporting the hypothesis that proteolytic caspases are present in the cell membrane ( Figure 4I ). Finally, we explored whether elastolytic enzymes are exteriorized to the cell surface after apoptosis by growing Fbn1 arises as a result of degraded DQ-elastin. Taken together, these data demonstrate that apoptotic Fbn1 C1039G/+ aortic root/ ascending SMCs degrade elastin, in vitro ( Figure 4J ).
Additional support for our hypothesis that caspases are exteriorized to the surface of the cell membrane after apoptosis was obtained by staining nonpermeabilized apoptotic Fbn1 C1039G/+ aortic root/ascending SMCs for cleaved caspase-3 and demonstrating the presence of cleaved caspase-3 on the cell membrane surface by fluorescence microscopy ( Figure 5A , 5B and 5C). Even more, scanning electron microscopic (EM) imaging of either nonpermeabilized, apoptotic ( Figure 5D and 5E) or viable ( Figure 5F and 5G) Fbn1 C1039G/+ and WT aortic root/ascending SMCs stained with cleaved caspase-3 and a gold-labeled secondary antibody confirmed that caspase-3 is localized to the external cell membrane surface.
Discussion
Aortic vascular SMC apoptosis has been reported in both human thoracic and abdominal aortic aneurysms after surgical resection. 12 However, its causal role during early aneurysm development in Marfan syndrome remains controversial. 13, 14 Specifically, whether media wall SMC apoptosis is a (1) key initiating event during aneurysm development or (2) secondary outcome ensuing from inflammatory injury or ECM remodeling remains undefined. In the present study, using the Marfan Fbn1 C1039G/+ mouse model system, in vivo single-photon emission computed tomographic-imaging reveals early enhanced apoptosis localized to the aortic root/ascending aorta, but absent in the descending and abdominal aortas, correlating temporally and spatially with subsequent aortic root/ascending aorta aneurysm development. As biological proof of concept that apoptosis participates in the pathogenesis of aneurysm development, treatment of mice with a pan-caspase-inhibitor (Q-VD-OPh) reduced early aortic root/ascending aortic aneurysm dimensions. Although several investigators have examined the role of apoptosis in abdominal aortic aneurysm models, [15] [16] [17] to the best of our knowledge, this is the first report that confirms the role of apoptosis during aneurysm development in the aortic root/ascending, specifically in MFS.
In the present study, we make use of a well-established Marfan mouse model (heterogeneous for a fibrillin 1 [Fbn1] allele encoding a cysteine to glycine substitution) that reproducibly develops aortic root/ascending aortic aneurysms, thus recapitulating the pathology observed in human MFS. We think that this in vivo genetic model system is an excellent experimental tool to evaluate the role that apoptosis plays during the pathogenesis of early aneurysm development. Daugherty's laboratory has described an ascending aortic aneurysm model system after chronic angiotensin II infusion in hypercholesterolemic mice. 18 Angiotensin II-induced ascending aneurysms have widespread macrophage infiltration, extensive elastin fragmentation, and concentric media thickening most pronounced near the adventitial aspect of the aorta. In contrast to the hypothesized central pathological role of SMCs presented in the Marfan model, Rateri et al elegantly used bone marrow transplant experiments to illustrate that endothelial cells, rather than SMCs, are the important angiotensin II responsive cell type in their model system. 19 Likely the cross talk between endothelial cells and SMCs will prove critical during aneurysm formation.
Results from this study provide a novel role for SMC apoptosis in early aneurysm development in MFS. We show that after SMC apoptosis, caspases are partially exteriorized to the cell membrane and hypothesize that these exteriorized caspases directly degrade the aortic wall ECM. Supporting this theory, Fbn1 C1039G/+ mice treated with a pan-caspase-inhibitor (Q-VDOPh) have reduced media wall elastin fragmentation. Even more, confocal microscopy revealed that caspase-3 partially localizes to the SMC plasma cell membrane in Fbn1 C1039G/+ mice, an effect blocked by treatment with the caspase-inhibitor. Because fluorescence microscopy cannot confirm whether cleaved caspase-3 is actually located on the exterior surface versus interior surface of the cell, we subsequently performed scanning EM on Fbn1 C1039G/+ and WT ascending aorta SMCs (in vitro) and demonstrated cleaved caspase-3 on the external cell membrane surface of nonpermeabilized apoptotic cells. Similar levels of caspase-3 on the cell surface of both Fbn1 C1039G/+ and WT SMCs suggest that enhanced caspase membrane transport after the apoptotic process is phenotype independent. Corroborating our theory, Cowan 9 et al reported that caspases-2, -3, and -7 are present on the plasma membrane of apoptotic SMCs in vitro. 9 How caspases are transported from the cytosol to the external cell surface remains a mystery. Possible mechanisms include intracellular targeting to the cell membrane, secretion followed by binding to a cell surface receptor, or activation of enzymes that move caspases across the membrane in both directions. 9, 20 In contrast to our findings, Gomez et al recently reported rare frequency of apoptotic cells within the aortic wall in human thoracic ascending aortic aneurysms (Marfan, bicuspid aortic valve, and degenerative), as well as resistance to apoptosis in cultured SMCs derived from the same specimens. Importantly, the specimens and vascular SMCs were taken from patients who already developed aneurysms, whereas our model studies early aneurysm pathogenesis (2-6 weeks) in an animal model. Although the best available option when studying human tissue, the authors hypothesize that apoptosis resistance in human aneurysm specimens likely represents a compensatory epigenetic reprogramming response to the disease process, instead of an initiating event. 21 Importantly, apoptosis of aortic root/ascending aortic SMCs cannot explain localized aneurysm growth alone because aneurysms still develop in Marfan mice despite caspase-inhibition, albeit at a slower growth rate. In addition, we cannot exclude the possibility that the caspase-inhibitor cross reacts and blocks other matrix-degrading enzymes. 22 Because only low levels of cleaved caspase-3 are histologically detected on the cell membrane in vivo, we think that other matrix-degrading enzymes probably play a part in aneurysm progression. Even more, the number of elastic lamellear interruptions is considerably fewer than anticipated in the areas surrounding apoptotic SMCs. Loss of aortic wall SMCs via apoptosis may also contribute to aneurysm development through other mechanisms. 23 Given that SMCs represent the major source of ECM protein production, apoptosis of SMCs may reduce the ability to repair connective tissue loss during early vessel wall remodeling and development. 24 Indeed, our laboratory has previously reported that reduced elastogenesis coincides with increased apoptosis during early aneurysm development in this model system. 4 This theory would seem less likely in our animal model, given that the total number of aortic wall SMCs remained unchanged, despite increased apoptosis. Several groups propose that SMC apoptosis promotes aortic wall macrophage recruitment, 25 major sources of ECM-degrading enzymes, including the matrix metalloproteinases. 13, 24, 26 Although our laboratory has reported that MMPs participate in aneurysm development in Marfan Fbn1 C1039G/+ mice, 4 the absence of inflammatory cell infiltration suggests that apoptotic SMCs must contribute to early aneurysm development through an alternative mechanism.
In conclusion, this study provides new insights into the pathogenesis of early aortic root/ascending aortic aneurysm development in MFS. Although low levels of vascular SMC apoptosis probably represent normal vessel wall development and remodeling, SMC apoptosis is enhanced in MFS. Although the precise mechanism remains to be determined, our results suggest that increased early aortic root/ascending aorta SMC apoptosis in Fbn1 C1039G/+ mice may be a key initiating event during the pathogenesis of aneurysm development in MFS. Pharmacological inhibitors that target and reduce apoptosis may represent a novel therapeutic strategy to slow aneurysm growth in MFS.
